Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy J Li, KT Byrne, F Yan, T Yamazoe, Z Chen, T Baslan, LP Richman, JH Lin, ... Immunity 49 (1), 178-193. e7, 2018 | 573 | 2018 |
Bruton tyrosine kinase–dependent immune cell cross-talk drives pancreas cancer AJ Gunderson, MM Kaneda, T Tsujikawa, AV Nguyen, NI Affara, B Ruffell, ... Cancer discovery 6 (3), 270-285, 2016 | 455 | 2016 |
The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer KA Michaelis, MA Norgard, X Zhu, PR Levasseur, S Sivagnanam, ... Nature communications 10 (1), 1-15, 2019 | 159 | 2019 |
Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer KT Byrne, CB Betts, R Mick, S Sivagnanam, DL Bajor, DA Laheru, ... Clinical Cancer Research 27 (16), 4574-4586, 2021 | 102 | 2021 |
Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome SM Liudahl, CB Betts, S Sivagnanam, V Morales-Oyarvide, A Da Silva, ... Cancer discovery 11 (8), 2014-2031, 2021 | 92 | 2021 |
High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers G Banik, CB Betts, SM Liudahl, S Sivagnanam, R Kawashima, T Cotechini, ... Academic Press, 2019 | 64 | 2019 |
B cells as biomarkers: predicting immune checkpoint therapy adverse events SM Liudahl, LM Coussens The Journal of clinical investigation 128 (2), 577-579, 2018 | 43 | 2018 |
Quantitative spatial profiling of immune populations in pancreatic ductal adenocarcinoma reveals tumor microenvironment heterogeneity and prognostic biomarkers H Mi, S Sivagnanam, CB Betts, SM Liudahl, EM Jaffee, LM Coussens, ... Cancer research 82 (23), 4359-4372, 2022 | 35 | 2022 |
To Help or To Harm: Dynamic Roles of CD4+ T Helper Cells in Solid Tumor Microenvironments SM Liudahl, LM Coussens Immunology, 97-116, 2018 | 22 | 2018 |
Innate αβ T cells mediate antitumor immunity by orchestrating immunogenic macrophage programming M Hundeyin, E Kurz, A Mishra, JAK Rossi, SM Liudahl, KR Leis, ... Cancer discovery 9 (9), 1288-1305, 2019 | 20 | 2019 |
Tumor-Infiltrating Leukocyte Phenotypes Distinguish Outcomes in Related Patients With Pancreatic Adenocarcinoma JM Link, SM Liudahl, CB Betts, S Sivagnanam, KR Leis, M McDonnell, ... JCO Precision Oncology 5, 344-356, 2021 | 2 | 2021 |
Abstract CT005: T cell inflammation in the tumor microenvironment after agonist CD40 antibody: Clinical and translational results of a neoadjuvant clinical trial KT Byrne, CB Betts, R Mick, S Sivagnanam, DL Bajor, DA Laheru, ... Cancer Research 81 (13_Supplement), CT005-CT005, 2021 | | 2021 |
Activation vs. Organization: Prognostic Implications of T and B Cell Features of the PDAC Microenvironment E Gray, S Liudahl, S Sivagnanam, C Betts, J Link, D Keith, B Sheppard, ... Mathematical and Computational Oncology: Second International Symposium …, 2020 | | 2020 |
Publisher Correction: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer KA Michaelis, MA Norgard, X Zhu, PR Levasseur, S Sivagnanam, ... Nature communications 10 (1), 1-1, 2019 | | 2019 |
Immune Contexture of Pancreatitis and Pancreatic Cancer: Implications for Immunotherapy: A Dissertation SM Liudahl Oregon Health & Science University, 2019 | | 2019 |